A Trial of the Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients (LAMRCT)

Clinical Trial ID NCT01770730

PubWeight™ 7.11^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01770730

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study.	Lancet Infect Dis	2011	7.23
2	Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients.	Eur Respir J	2012	2.45
3	Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial.	Lancet	2016	1.71
4	Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis.	AIDS	2015	1.68
5	Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies.	BMC Infect Dis	2013	1.49
6	Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.	BMC Med	2016	0.87
7	Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications.	Trans R Soc Trop Med Hyg	2016	0.83
8	Urine antigen test for diagnosis of HIV-associated tuberculosis.	Lancet Infect Dis	2012	0.81
9	Comparative performance characteristics of the urine lipoarabinomannan strip test and sputum smear microscopy in hospitalized HIV-infected patients with suspected tuberculosis in Harare, Zimbabwe.	BMC Infect Dis	2016	0.78